| Rebecca Wanting Tsang, MD, MPH | |
|
2150 Pfingsten Rd Ste 3000, Glenview, IL 60026-1314 | |
| (847) 657-1900 | |
| Not Available |
| Full Name | Rebecca Wanting Tsang |
|---|---|
| Gender | Female |
| Speciality | Gastroenterology |
| Experience | 14 Years |
| Location | 2150 Pfingsten Rd Ste 3000, Glenview, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043531528 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 125-058624 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northshore University Healthsystem - Evanston Hospital | Evanston, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Shore University Healthsystem Faculty Practice Associates | 2163334699 | 1751 |
News Archive
Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV).
Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.
A perspective piece in this week's issue of the New England Journal of Medicine from a student at the University of Pennsylvania's Perelman School of Medicine addresses the evolution of diversity in medical education.
An article, published in Circulation by Laurel K. Leslie, MD, MPH from the Tufts Clinical and Translational Science Institute (CTSI) and colleagues from Tufts Medical Center and Floating Hospital for Children at Tufts Medical Center, has evaluated the lifesaving benefits and costs of screening programs for the prevention of sudden cardiac death (SCD) in children and adolescents.
The American Society of Clinical Oncology has developed a set of recommendations to address whether patients who have had successful surgery for Stage II colon cancer should be offered adjuvant chemotherapy in routine clinical practice.
› Verified 2 days ago
| Entity Name | Northshore University Healthsystem Faculty Practice Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497701882 PECOS PAC ID: 2163334699 Enrollment ID: O20040524000118 |
News Archive
Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV).
Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.
A perspective piece in this week's issue of the New England Journal of Medicine from a student at the University of Pennsylvania's Perelman School of Medicine addresses the evolution of diversity in medical education.
An article, published in Circulation by Laurel K. Leslie, MD, MPH from the Tufts Clinical and Translational Science Institute (CTSI) and colleagues from Tufts Medical Center and Floating Hospital for Children at Tufts Medical Center, has evaluated the lifesaving benefits and costs of screening programs for the prevention of sudden cardiac death (SCD) in children and adolescents.
The American Society of Clinical Oncology has developed a set of recommendations to address whether patients who have had successful surgery for Stage II colon cancer should be offered adjuvant chemotherapy in routine clinical practice.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rebecca Wanting Tsang, MD, MPH 2150 Pfingsten Rd Ste 3000, Glenview, IL 60026-1314 Ph: (847) 657-1900 | Rebecca Wanting Tsang, MD, MPH 2150 Pfingsten Rd Ste 3000, Glenview, IL 60026-1314 Ph: (847) 657-1900 |
News Archive
Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV).
Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.
A perspective piece in this week's issue of the New England Journal of Medicine from a student at the University of Pennsylvania's Perelman School of Medicine addresses the evolution of diversity in medical education.
An article, published in Circulation by Laurel K. Leslie, MD, MPH from the Tufts Clinical and Translational Science Institute (CTSI) and colleagues from Tufts Medical Center and Floating Hospital for Children at Tufts Medical Center, has evaluated the lifesaving benefits and costs of screening programs for the prevention of sudden cardiac death (SCD) in children and adolescents.
The American Society of Clinical Oncology has developed a set of recommendations to address whether patients who have had successful surgery for Stage II colon cancer should be offered adjuvant chemotherapy in routine clinical practice.
› Verified 2 days ago
Karen Chiu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2100 Pfingsten Rd Ste 3001a, Glenview, IL 60026 Phone: 847-657-5840 Fax: 847-657-5732 | |
Lynn K. Martin, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2550 Waukegan Rd, Suite 100, Glenview, IL 60025 Phone: 847-729-2541 Fax: 847-729-2546 | |
Dr. Jamee Castillo Tantoco, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2050 Pfingsten Rd Ste 320, Glenview, IL 60026 Phone: 847-998-4170 Fax: 847-998-4165 | |
Dr. Gregory Aaron Wallman, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2501 Compass Rd, Suite 100, Glenview, IL 60026 Phone: 847-901-5200 Fax: 847-904-4907 | |
Dr. Monica S. Borkar, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2100 Pfingsten Rd, Suite B230, Glenview, IL 60026 Phone: 847-657-1900 Fax: 847-657-1961 | |
Joel R. Green, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2100 Pfingsten Rd Ste 3001a, Glenview, IL 60026 Phone: 847-657-5840 Fax: 847-657-5835 |